StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research note published on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
A number of other research analysts have also recently commented on ACRX. Alliance Global Partners assumed coverage on AcelRx Pharmaceuticals in a research report on Monday, October 2nd. They set a buy rating and a $4.25 price target on the stock. HC Wainwright dropped their price target on AcelRx Pharmaceuticals from $8.00 to $5.00 and set a buy rating on the stock in a research report on Monday, September 25th.
AcelRx Pharmaceuticals Trading Up 1.3 %
Institutional Trading of AcelRx Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in ACRX. Vanguard Group Inc. raised its stake in shares of AcelRx Pharmaceuticals by 22.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,569,553 shares of the specialty pharmaceutical company’s stock valued at $955,000 after purchasing an additional 831,999 shares during the period. Armistice Capital LLC bought a new stake in shares of AcelRx Pharmaceuticals during the 4th quarter valued at $830,000. Virtu Financial LLC bought a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $29,000. Cowen AND Company LLC bought a new stake in shares of AcelRx Pharmaceuticals during the 3rd quarter valued at $67,000. Finally, Values First Advisors Inc. raised its stake in shares of AcelRx Pharmaceuticals by 201.7% during the 2nd quarter. Values First Advisors Inc. now owns 122,441 shares of the specialty pharmaceutical company’s stock valued at $136,000 after purchasing an additional 81,854 shares during the period. 19.79% of the stock is currently owned by institutional investors.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain.
- Five stocks we like better than AcelRx Pharmaceuticals
- Investing in Agriculture 101: How to Invest in Agriculture
- The most upgraded stocks in November have two things in common
- What Are Dividend Achievers? An Introduction
- Monday.com rocked earnings like it’s the weekend
- The How and Why of Investing in Gold Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.